ReviewCurrent gastroenterology reports2013
Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?
Review in Current gastroenterology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use.Cytokine & growth factor reviews · 2015Review
- Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.Hepatology (Baltimore, Md.) · 2014Article
- Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) RNA level monitoring is currently used to guide the duration of interferon-containing treatment regimens. Nowadays, HCV RNA level quantification is based on real-time polymerase chain reaction assays that are both sensitive and accurate. Assessing the virological response to therapy is used to shorten treatment duration in early responders, in order to reduce the cost and burden of adverse events of therapy without impacting the chance of success. Whether response-guided therapy will still be useful in the era of all-oral, interferon-free regimens remains uncertain.
Indexed as
Identifiers
23314805What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.